Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 7/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30805945 | 0.88 | CLK1 (0.57) | CLK1HDAC6DYRK1ADYRK1BPTPN2 | |
| SCHEMBL15697592 | 0.88 | CLK1 (0.57) | CLK1HDAC6DYRK1ADYRK1BPTPN2 | |
| SCHEMBL3641154 | 0.88 | CHRNA7 (0.51) | CLK1BCL2L1PIM1TBXAS1HDAC6 | |
| SCHEMBL27352409 | 0.87 | CDK8 (0.54) | CLK1PIM1HDAC6DYRK1ADYRK1B | |
| SCHEMBL30805959 | 0.87 | CDK8 (0.54) | CLK1PIM1HDAC6DYRK1ADYRK1B | |
| SCHEMBL18003474 | 0.82 | PTPN2 (0.54) | CLK1HDAC6DYRK1ADYRK1BPTPN2 | |
| SCHEMBL15697564 | 0.80 | AKR1C2 (0.49) | BCL2L1HDAC6GPR35DYRK1APTPN2 | |
| SCHEMBL1867721 | 0.80 | CLK1 (0.68) | CLK1BCL2L1DYRK1ADYRK1BCLK2 | |
| SCHEMBL5565033 | 0.77 | KMT2A (0.60) | CLK1BCL2L1TBXAS1GPR35DYRK1A | |
| SCHEMBL1367894 | 0.77 | HDAC6 (0.45) | CLK1PIM1HDAC6DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| EP-4561991-A1 | NOVEL HETEROCYCLES AS SPLA2-X INHIBITORS | Cayman Chemical Company, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2926660-A1 | METHOD FOR PROMOTING PLANT GROWTH | Sumitomo Chemical Company Limited (JP) | 2015-10-07 | — | — | EP | disclosed |
| EP-2926660-A1 | METHOD FOR PROMOTING PLANT GROWTH | Sumitomo Chemical Company Limited (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-8906914-B2 | Ethylene diamine modulators of fatty acid hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-09 | — | — | US | disclosed |
| WO-2014073623-A1 | METHOD FOR PROMOTING PLANT GROWTH | 住友化学株式会社 (JP) | 2014-05-15 | — | — | WO | disclosed |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | US | disclosed |
| WO-2011022348-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | WO | disclosed |
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150289506-A1 | METHOD FOR PROMOTING PLANT GROWTH | FGF2, BROX, BOLA2; BOLA2B | CLK1 2197/4885BCL2L1 2137/4885PIM1 2770/4885 |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | FAAH, FAAH2, APEH | CLK1 3385/4885BCL2L1 2109/4885PIM1 4786/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | CLK1 4466/4885BCL2L1 3789/4885PIM1 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.